Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Seagen

Pharma giant Merck nearing possible $40 billion acquisition of Washington-based Seagen

Bothell-based Seagen may be acquired by pharma giant Merck in a deal valued at $40 billion, The Wall Street Journal reported Wednesday.

Tribune News Service

Stock Market Indexes See More Green As Health Care Stocks Hit Buy Points

The major stock market indexes are near the highs of the day at midday.

Investors Business Daily

Nasdaq, Small Caps Lead Stock Market; Health Care Up As 2 Stocks Top Buy Points

The Nasdaq jumped 1.3%, the S&P 500 rose 0.9% and the Dow Jones Industrial Average added 0.6%.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

The Daily Biotech Pulse: Merck's Seagen Buyout Advances, Adverum Restructures, Pharmacists Get OK To Prescribe Pfizer COVID-19 Pill

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Merck Reportedly Eyes $40 Billion Seagen Tie-Up; Will The Deal Save Biotech?

Merck is now in advanced talks to buy Seagen for roughly $40 billion, according to reports that sent SGEN stock higher Thursday.

Investors Business Daily

Benzinga Before The Bell: Elon Musk's Kids, Apple's Potential Security Measure, Covid-19 Vaccine Wastage And Other Top Financial Stories Thursday, July 7

CNBC

Benzinga

$1000 Invested In This Stock 5 Years Ago Would Be Worth $3,400 Today

Seagen (NASDAQ:SGEN) has outperformed the market over the past 5 years by 18.41% on an annualized basis producing an average annual return of 27.81%. Currently, Seagen has a market capitalization of $32.98 billion.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

This Analyst Believes Seagen Is Evaluating Strategic Alternatives

Raymond James initiated coverage on Seagen Inc (NASDAQ:SGEN) at Outperform with a $220 target price. Citing the recent departure of the long-time Seagen CEO, Raymond James thinks that the Board of Directors is likely evaluating strategic alternatives for the company. The relationship with Merck & Company, Inc. (NYSE:MRK) has been long-standing. With Keytruda losing its patent…

Benzinga

Stock Market Closes Higher, Snapping 3-Week Losing Streak; FedEx, Salesforce Lead Gains

The stock market closed higher Friday, snapping a 3-week losing streak on new data pointed to a slowing economy.

Investors Business Daily

Dow Up Over 650 Points; Health Care, Biotechs The Winners This Week

The Nasdaq is on pace for a 6.4% gain for the week, while the S&P 500 is up 5.7%.

Investors Business Daily

Seagen Surges As Merck Takeover Deal Reportedly Accelerating

Merck is reportedly nearing a takeover of cancer biotech Seagen, according to a report Friday that prodded SGEN stock higher.

Investors Business Daily

Dow Jones Jumps In Broad Rally; Zendesk Spikes On Buyout, China Stocks Keep Rising

Futures rose, with crude oil and Treasury yields also up. Zendesk soared on a buyout. Li Auto, Alibaba led China stocks higher.

Investors Business Daily

Merck/Seagen Potential Deal Talks Pick Up Speed: WSJ

Merck & Co Inc (NYSE:MRK) is pushing forward with a potential deal for Seagen Inc (NASDAQ:SGEN), Wall Street Journal reported, citing people familiar with the matter. The Journal mentioned that the deal could be one of the largest takeovers of the year. The Wall Street Journal reported last week that Merck was in talks to…

Benzinga

Where Seagen Stands With Analysts

Analysts have provided the following ratings for Seagen (NASDAQ:SGEN) within the last quarter:

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

SVB Leerink's Pro-forma Analysis Of Speculated Merck/Seagen Deal - What Investors Need To Know

SVB Securities conducted a pro-forma analysis of the financial impact to Merck & Co Inc (NYSE: MRK) from a potential acquisition of Seagen Inc (NASDAQ: SGEN).

Investors Business Daily

Stock Market Closes Higher, But Dow Jones Inches Down; Exxon And Chevron Lead Oil Stocks Lower

The stock market gained but the Dow Jones inched lower on the eve of three-day weekend. Oil stocks tumble.

Investors Business Daily

Stock Market Ending Week With Gains But Energy Stocks Continue To Slide

Crude oil futures have fallen nearly 7% today, to $109 per barrel.

Benzinga

33 Stocks Moving In Friday's Mid-Day Session

Gainers Revlon, Inc. (NYSE: REV) gained 81.5% to $3.54 following a report suggesting Reliance Industries is considering buying out the company, which recently filed for bankruptcy.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Embattled Biotech Seagen Rockets On Rumors Merck Could Buy It

Merck is reportedly eyeing a takeover of embattled biotech Seagen, according to multiple reports that sent SGEN stock flying Friday.

Benzinga

Merck Shows Takeover Interest In Seagen: WSJ

Merck & Co Inc (NYSE:MRK) is reportedly mulling buying cancer-focused biotech Seagen Inc (NASDAQ:SGEN), Wall Street Journal reported citing people familiar with the matter. If the deal happens, it would be significant, given Seagen's market value of roughly $28 billion. According to the report, some people said other unnamed suitors are also eying Seagen, a…

Benzinga

$100 Invested In Seagen 20 Years Ago Would Be Worth This Much Today

Seagen (NASDAQ:SGEN) has outperformed the market over the past 20 years by 12.54% on an annualized basis producing an average annual return of 19.38%. Currently, Seagen has a market capitalization of $26.91 billion.

Benzinga

$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,200 Today

Seagen (NASDAQ:SGEN) has outperformed the market over the past 5 years by 5.77% on an annualized basis producing an average annual return of 17.01%. Currently, Seagen has a market capitalization of $26.17 billion.

Benzinga

Seagen Posts Encouraging Data From Tucatinib Combo Trial In Colorectal Cancer

Seagen Inc (NASDAQ:SGEN) announced topline results from phase 2 MOUNTAINEER trial investigating Tukysa (tucatinib) in combination with trastuzumab in previously treated HER2-positive metastatic colorectal cancer (mCRC) patients. Trastuzumab is sold under the name Herceptin by Genentech, a unit of Roche Holdings AG (OTC:RHHBY). Data from this trial will form the basis of a planned supplemental…

Investors Business Daily

Seagen CEO Clay Siegall Resigns After Domestic Violence Arrest

Seagen Chief Executive Clay Siegall resigned Monday amid domestic violence allegations, and SGEN stock inched up.

Benzinga

Amid Domestic Violence Allegation, Longtime Seagen CEO Takes Leave of Absence

The Board of Directors of Seagen Inc (NASDAQ:SGEN) announced that its long-time president, CEO, and chairman Clay Siegall, is on a leave of absence. The move follows an alleged incident of domestic violence. While Siegall, who informed the company that he's in the middle of a divorce, denied those allegations. The Seagen board…

1 2 3 4

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Dow Jones Industrial Average

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.